Skip to main content

Advertisement

Figure 6 | Arthritis Research & Therapy

Figure 6

From: Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

Figure 6

In vitro effect of tumour necrosis factor (TNF) antagonists on anti-mycobacterial proliferative response. In patients with previous or latent TB, lymphocyte proliferation was determined using the thymidine incorporation assay after 5 days of activation with purified protein derivative (PPD) in the presence of 10 μg/ml of a control antibody (-) or of infliximab (Ifx), adalimumab (Ada), or etanercept (Eta) (a). In patients with previous or latent TB, lymphocyte proliferation was determined using the thymidine incorporation assay after 5 days of activation with culture filtrate protein (CFP)-10 in the presence of 10 μg/ml of a control antibody (-) or of infliximab (Ifx), adalimumab (Ada), or etanercept (Eta) (b). Twelve patients were tested: four from group II, before TNF antagonist administration, and eight from group IV, with similar findings in both cases. (c) Graded concentrations of TNF antagonists were added to PPD-stimulated cells (n = 9). Results are expressed as stimulation indices SIs (mean ± standard error of the mean (SEM). *p < 0.05 for paired comparison between Ifx, Ada, or Eta and the control antibody (Wilcoxon test with Bonferroni corrections).

Back to article page